Urinary Tract Infections - Pipeline Review, H2 2015

Date: September 30, 2015
Pages: 139
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U8B398806F8EN
Leaflet:

Download PDF Leaflet

Urinary Tract Infections - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Urinary Tract Infections - Pipeline Review, H2 2015’, provides an overview of the Urinary Tract Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Urinary Tract Infections Overview
Therapeutics Development
Pipeline Products for Urinary Tract Infections - Overview
Pipeline Products for Urinary Tract Infections - Comparative Analysis
Urinary Tract Infections - Therapeutics under Development by Companies
Urinary Tract Infections - Therapeutics under Investigation by Universities/Institutes
Urinary Tract Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Urinary Tract Infections - Products under Development by Companies
Urinary Tract Infections - Products under Investigation by Universities/Institutes
Urinary Tract Infections - Companies Involved in Therapeutics Development
Achaogen Inc.
Adenium Biotech ApS
AstraZeneca Plc
ConjuGon, Inc.
Da Volterra
DexTech Medical AB
Enteris BioPharma, Inc.
GlaxoSmithKline Plc
Melinta Therapeutics, Inc
Merck & Co., Inc.
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics AG
Nippon Shinyaku Co., Ltd.
NovaBay Pharmaceuticals, Inc.
Nymox Pharmaceutical Corporation
Paratek Pharmaceuticals, Inc.
Pivot Pharmaceuticals Inc
Sequoia Sciences, Inc.
Shionogi & Co., Ltd.
Syntiron LLC
The Medicines Company
Zensun (Shanghai) Sci & Tech Co., Ltd.
Urinary Tract Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ceftazidime + avibactam sodium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(meropenem+ RPX-7009) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AA-139 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
auriclosene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-7634 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-9074 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-9529 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-9563 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-1205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CatDex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cefepime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DAV-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit COX-2 for Urinary Tract Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EBX-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Escherichia coli vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fosfomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GP-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-63871860 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Micselon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nu-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NXB-4221 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteins for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prulifloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relebactam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-649266 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tobramycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
urinary tract infection vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZS-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Urinary Tract Infections - Recent Pipeline Updates
Urinary Tract Infections - Dormant Projects
Urinary Tract Infections - Discontinued Products
Urinary Tract Infections - Product Development Milestones
Featured News & Press Releases
Sep 17, 2015: Paratek's Omadacycline, Demonstrates Broad Spectrum Activity in Pathogens Relevant in Skin Infections, Community-Acquired Pneumonia and Urinary Tract Infections
Sep 02, 2015: Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
Aug 03, 2015: Paratek Pharmaceuticals to Present Data at ICAAC 2015
Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
Apr 27, 2015: Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
Apr 23, 2015: Actavis Launches AVYCAZ (Ceftazidime-Avibactam) Anti-Infective In U.S.
Apr 09, 2015: Achaogen to Present at 14th Annual Needham Healthcare Conference
Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Urinary Tract Infections, H2 2015
Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Investigation by Universities/Institutes, H2 2015
Urinary Tract Infections - Pipeline by Achaogen Inc., H2 2015
Urinary Tract Infections - Pipeline by Adenium Biotech ApS, H2 2015
Urinary Tract Infections - Pipeline by AstraZeneca Plc, H2 2015
Urinary Tract Infections - Pipeline by ConjuGon, Inc., H2 2015
Urinary Tract Infections - Pipeline by Da Volterra, H2 2015
Urinary Tract Infections - Pipeline by DexTech Medical AB, H2 2015
Urinary Tract Infections - Pipeline by Enteris BioPharma, Inc., H2 2015
Urinary Tract Infections - Pipeline by GlaxoSmithKline Plc, H2 2015
Urinary Tract Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
Urinary Tract Infections - Pipeline by Merck & Co., Inc., H2 2015
Urinary Tract Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2015
Urinary Tract Infections - Pipeline by Nabriva Therapeutics AG, H2 2015
Urinary Tract Infections - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
Urinary Tract Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015
Urinary Tract Infections - Pipeline by Nymox Pharmaceutical Corporation, H2 2015
Urinary Tract Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2015
Urinary Tract Infections - Pipeline by Pivot Pharmaceuticals Inc, H2 2015
Urinary Tract Infections - Pipeline by Sequoia Sciences, Inc., H2 2015
Urinary Tract Infections - Pipeline by Shionogi & Co., Ltd., H2 2015
Urinary Tract Infections - Pipeline by Syntiron LLC, H2 2015
Urinary Tract Infections - Pipeline by The Medicines Company, H2 2015
Urinary Tract Infections - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Urinary Tract Infections Therapeutics - Recent Pipeline Updates, H2 2015
Urinary Tract Infections - Dormant Projects, H2 2015
Urinary Tract Infections - Dormant Projects (Contd.1), H2 2015
Urinary Tract Infections - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Urinary Tract Infections, H2 2015
Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Achaogen Inc.
Adenium Biotech ApS
AstraZeneca Plc
ConjuGon, Inc.
Da Volterra
DexTech Medical AB
Enteris BioPharma, Inc.
GlaxoSmithKline Plc
Melinta Therapeutics, Inc
Merck & Co., Inc.
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics AG
Nippon Shinyaku Co., Ltd.
NovaBay Pharmaceuticals, Inc.
Nymox Pharmaceutical Corporation
Paratek Pharmaceuticals, Inc.
Pivot Pharmaceuticals Inc
Sequoia Sciences, Inc.
Shionogi & Co., Ltd.
Syntiron LLC
The Medicines Company
Zensun (Shanghai) Sci & Tech Co., Ltd.
Skip to top


Ask Your Question

Urinary Tract Infections - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: